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In a retrospective program evaluation analysis, we compared abstinence rates in 
78 smokers participating in a 2-, 3-, or 6-week clinic-based behavioral- 
pharmacological smoking cessation program. The  three treatment formats con- 
sisted of six sessions that varied ill session frequency. Retention and end-of- 
t reatment smoking cessation rates were best in the medium-frequency (3-week) and 
high-frequency (2-week) treatment session formats. One-year follow-up abstinence 
rates were highest in the medium-frequency format, and lowest in the high- 
fi'equency [ormat. A significant pa t ient - t rea tment  interaction effect was found for 
pretreatment  smoking rate. Individuals with lower pretreatment smoking rates ben- 
efited most with respect to end-of-treatment cessation rates from the medium- and 
high-fi'equency treatment session format. However, this effect was not significant at 
the l-year follow-up. The  need for prospective research and patient-to-treatment 
matching implications in smoking cessation programs are discussed. 
A large body of  literature exists on various methods used to help smokers quit 
successfully (Lichtenstein & Glasgow, 1992). In recent years, the focus of smok- 
ing intervention research has shifted from the development of new, innovative 
techniques to the refinement of various treatment components. There  is grow- 
ing interest in the possibility of improving treatment outcome by matching 
smokers to treatments designed to meet their specific needs (e.g., Stevens & Hol- 
lis, 1989). 
A popular clinic-based smoking cessation treatment is one that employs be- 
havioral self-regulation and relapse prevention training with adjunctive phar- 
macological therapy (Carmody, 1992). Studies that have examined ways to 
optimize this treatment approach have focused on a variety of "therapeutic" 
components, such as type of skills trained (Emmons, Emont, Collins, & Weidner, 
1988) and schedule of  nicotine gum administration (Goldstein, Niaura, Follick, 
& Abrams, 1989). Another set of  potential matching variables are those associ- 
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ated with how the treatment process is organized and presented to clients. Deci- 
sions regarding treatment delivery factors are often based on pragmatic and 
economic considerations, rather than empirical evidence. One notable exception 
is the work of  Lando (1987), who evaluated the relative effectiveness of  lay ver- 
sus professional facilitators in conducting smoking cessation programs. 
This article presents findings that emerged from a retrospective smokifig ces- 
sation program evaluation analysis. The clinic-based behavioral-pharmacological 
program for smoking cessation included six treatment sessions that, due to prac- 
tical considerations, were delivered in 6 weeks (1 session per week), 3 weeks (2 
sessions per week), or 2 weeks (3 sessions per week). Although treatment content 
remained the same, the frequency with which these sessions were delivered 
emerged as a significant predictor of  dropout, initial quit rate, and 1-year sus- 
tained abstinence. In addition to treatment format, we examined other variables 
that might interact with format to predict treatment success. 
METHOD 
Subjects 
Smokers were recruited through posted announcements advertising a Tobac- 
co Independence Program (TIP). Seventy-eight persons enrolled in the pro- 
gram. This sample consisted of  33 men and 43 women. Table 1 contains data on 
pretreatment smoking history characteristics. Generally, the sample consisted of 
moderately heavy and dependent  smokers who had been smoking more than 5 
years. 
Measures 
A smoking history questionnaire was used to assess smoking-relevant vari- 
ables and included a 1-item motivation to quit smoking scale (0 = not at all to 8 = 
extremely). The Fagerstr6m Tolerance Questionnaire (FTQ; Fagerstr6m, 1978) 
was administered as a measure of  nicotine dependence (scale range = 1-11). 
The Smoking Self-Efficacy Questionnaire (SSEQ; Colletti, Supnick, & Payne, 
1985) was used to measure self-efficacy regarding not smoking in various high- 
risk situations (score range: 0-100). The 14-item Perceived Stress Scale (PSS; 
Cohen, Kamarck, & Mermelstein, 1983) measured the degree to which individu- 
als appraised situations in their lives as stressful (score range: 0-56). PSS scores 
have been found to be lower for quitters than for nonquitters in studies predict- 
ing successful outcome in smoking cessation (Glasgow, Klesges, Mizes, & 
Pechacek, 1985). 
Alveolar carbon monoxide (CO) levels were measured with the MiniCO Mod- 
el 1000 portable ecolyzer (Catalyst Research Corporation, Owings Mills, MD). A 
CO --< 10 ppm was used to indicate abstinence. Clients self-recorded daily smok- 
ing rate using small tally cards. These two measurements were collected at the 
start of  each treatment session. 
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Procedure 
All potential subjects participated in an initial telephone interview designed 
to explain the treatment program and evaluate eligibility to participate. To en- 
roll in the program, individuals had to be smoking at least 10 cigarettes per day, 
lacking severe psychiatric or medical problems, and able to attend six treatment 
sessions. As this was not a prospective study, patients were not assigned ran- 
domly to treatment groups. The procedure to assign cohorts to the treatment 
formats (6-, 3-, 2-week) was nonrandom and took into account staffing and space 
availability. Nevertheless, subjects did not self-select treatment format, and no 
patient characteristic determined format assignment. 
Treatment 
The TIP smoking treatment consisted of six 1-hour sessions delivered in 
group format (up to eight participants per group) by trained doctoral-level clini- 
cal psychology interns. Group leaders were supervised on a weekly basis by the 
first author. A detailed, session-by-session treatment manual was used by the 
group leaders. The smoking intervention employed in this study is representa- 
tive of  those currently offered in most formal cessation clinics. The structured 
behavioral-pharmacological treatment approach highlights four components: 
gradual nicotine fading, coping skills training, relapse prevention strategies, and 
nicotine replacement therapy (Nicotine Polacrilex) as a pharmacological treat- 
ment adjunct. Participants were instructed to select a target quit date between 
Sessions 4 and 5. 
The treatment program was delivered in three formats that differed with re- 
spect to the frequency of  sessions. In the low-frequency (LF) format, subjects 
participated in six weekly sessions. A total of  22 subjects were treated in this 
format, involving five cohorts over a 30-week period. In the medium-frequency 
(MF) format, the six treatment sessions were conducted over a 3-week period. 
The MF group consisted of  a total of  29 subjects, in six cohorts over a 32-week 
period. Finally, the high-frequency (HF) format involved six sessions conducted 
over a 2-week period. A total of  27 subjects were treated in the HF format (six 
cohorts over a 24-week period). Follow-up data collection sessions were held ap- 
proximately 12 months (r: 12-14 months) after the end of  treatment. Subjects 
who completed treatment were asked to return for a follow-up visit. Daily smok- 
ing rate and measurement of  smoking status were verified by CO levels. 
RESULTS 
Comparability of Conditions 
Univariate analyses of  variance (ANOVAs) for continuous measures and chi- 
square analyses for frequency variables revealed that there were no significant 
differences between groups on demographic or pretreatment smoking history 
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Table  1. Subjec t  P r e t r e a t m e n t  C h a r a c t e r i s t i c s  by  T r e a t m e n t  Format  
LF MF HF 
Characteristic (N = 22) (N = 29) (N = 27) 
Gender  
Male 11 11 11 
Female 11 18 16 
Ethnicity 
Caucasian 19 20 20 
Other  3 9 7 
Marital Status 
Married 8 12 8 
Divorced/Separated 10 8 10 
Single 4 9 9 
Employment 
Employed 15 21 23 
Unemployed 7 8 4 
Education (years) 
M 14.36 15.06 15.55 
SD 2.40 3.18 2.50 
Age 
M 39.36 42.13 40.87 
SD 7.22 10.96 9.75 
Cigarettes/day 
M 30.50 23.67 24.92 
SD 14.70 11.72 12.97 
Years Smoked 
M 16.40 19.58 16.36 
SD 9.75 11.87 8.57 
Longest Abstinence (days) 
M 103.68 235.03 122.18 
SD 159.69 337.21 262.67 
Nicotine Dependence (TQ score) 
M 7.76 7.75 6.94 
SD 1.89 1.74 1.95 
Motivation to Quit 
M 6.36 6.93 6.20 
SD 1.55 1.27 1.89 
Self-Efficacy (SSEQ score) 
M 47.36 44.74 52.31 
SD 18.06 19.01 15.37 
Stress (PSS score) 
M 26.72 24.96 24.45 
SD 6.43 7.70 6.75 
Note. LF = low frequency; MF = medium frequency; HF = high frequency; 
T Q  = Tolerance Questionnaire; SSEQ = Smoking Self-Efficacy Questionnaire; 
PSS = Perceived Stress Scale. 
measures. There  was a nonsignificant trend for subjects in the MF group to 
report  longer past abstinence periods; however, this apparent difference was 
caused by data from two subjects with extreme values (e.g., longest abstinence - 
5 years). Subsequent analyses, performed with and without removal of  these out- 
liers, yielded similar results. Descriptive information on these variables by treat- 
ment format is shown in Table 1. 
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Table 2. Treatment Retention, Quit Rates, and 1-Year Outcomes 
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LF MF HF 
Retention 
59.1% 79.4% 96% ×2(2) = 10.29, p < .006 
LF vs. MF ×2(1) = 2.46, n.s. 
LF vs. HF ×9(1) = 10.33, p < .001 
MF vs. HF X2(1) = 3.68, p < .05 
Quit Rates (end of treatment) 
With dropouts ~ 
22.7% 51.7% 55.5% X2(2) = 6.15, p < . 0 4  
LF vs. MF Xz(1) = 4.41,p < .03 
LF vs. HF ×~(1) = 5.40, p < .02 
MF vs. HF ×z(1) = 0.08, n.s. 
Without dropouts 
38.4% 65.2% 57.6% ×2(2) = 2.44, n.s. 
LF vs. MF X2(1) = 2.40, n.s. 
LF vs. HF X2(I) = 1.28, n.s. 
MF vs. HF ×~(1) = 0.29, n.s. 
1-Year Abstinence 
With lost to follow-up b 
22% 41% 7.4% X2(2) = 8.80, p < .01 
LF vs. MF X2(1) = 1.95, n.s. 
LF vs. HF X~(1) = 2.32, n.s. 
MF vs. HF ×2(1) -- 8.60, p < .003 
Without lost to follow-up 
40% 63% 11% X2(2) = 10.61, p < .005 
LF vs. MF X2(1) = 1.42, n.s. 
LF vs. HF X2(1) = 3.18, p < .07 
MF vs. HF X~(1) = 10.64, p < .001 
Note. LF = low frequency; MF = medium frequency; HF = high frequency. 
aWith dropouts included and classified as treatment failures. 
bWith subjects lost to follow-up included and classified as treatment failures. 
Treatment Retent ion,  Smoking  Reduct ion ,  and Q u i t t i n g  
Subjec ts  were  c o n s i d e r e d  to have c o m p l e t e d  t r e a t m e n t  if  they a t t e n d e d  50% 
of  the  t r e a t m e n t - - t h a t  is, at  least  t h ree  o f  the  six sessions. S igni f ican t ly  m o r e  
subjects  r ece iv ing  the  LF  a n d  MF fo rma t s  d r o p p e d  ou t  o f  t r e a t m e n t  c o m p a r e d  
to those  r ece iv ing  the  H F  f o r m a t  (see Tab le  2). Reanalyses  o f  g r o u p  d i f f e r e nc e s  
o n  d e m o g r a p h i c  a n d  p r e t r e a t m e n t  s m o k i n g  variables,  with d r o p o u t s  exc luded ,  
i n d i c a t e d  tha t  the  th ree  t r e a t m e n t  g r o u p s  r e m a i n e d  c o m p a r a b l e .  
To  test fo r  b e t w e e n - g r o u p  d i f f e rences  in  s m o k i n g  ra te  r e d u c t i o n  d u r i n g  t reat -  
m e n t ,  dai ly s m o k i n g  ra tes  were  ca lcu la ted  as a p e r c e n t a g e  o f  the  p r e t r e a t m e n t  
rate,  a n d  a two-fac tor  ( f o rma t  a n d  session) analysis  o f  va r i ance  with r e p e a t e d  
m e a s u r e s  o n  o n e  fac tor  (session) was p e r f o r m e d .  Subjects  who d r o p p e d  o u t  o f  
t r e a t m e n t  were  e x c l u d e d  f r o m  this analysis.  Repea t ed  A N O V A  resul ts  showed  a 
s ign i f i can t  dec rease  in  s m o k i n g  ra te  over  sessions,  F(4,  96) = 75.5, p < .0001, a 
s ign i f i can t  m a i n  ef fec t  for  fo rmat ,  F(2,  96) = 4.73, p < .01, a n d  a s ign i f i can t  
sess ion by f o r m a t  i n t e r a c t i o n ,  F(8,  96) = 2.04, p < .04. T u k e y  post  hoc c o m p a r i -  
82 J.M. Schmitz and J.C. Tate 
sons indicated that subjects in the MF group had significantly lower smoking 
rates at treatment Session 3 than LF and HF subjects. Significant differences 
between treatment conditions also were found at Session 5, with both MF and 
HF subjects reporting lower smoking rates than LF subjects. 
End-of-treatment abstinence rates between the LF, MF, and HF treatment 
format groups were not significantly different but clearly favored the shorter 
formats (see Table 2). The same analysis performed with dropouts included and 
classified as treatment failures yielded significant results, with higher abstinence 
rates found in the HF and MF formats as compared to the LF format (see Table 2). 
One-Year Outcome 
Sustained abstinence at the 1-year follow-up assessment was defined as a self- 
report of no tobacco use in the previous 12 months and CO - 10 ppm. Thirty 
subjects were lost to follow-up (38%). The lost to follow-up rate did not differ 
significantly between the three formats (LF = 45.4%, MF = 34.4%, HF = 37%; 
X2(2) = .73, n.s.). 
The number of abstinent smokers at 1-year posttreatment was dependent 
upon treatment format (see Table 2). More subjects in the MF format were absti- 
nent at follow-up than in the HF format. Abstinence rates of the MF and LF 
formats were not significantly different but clearly favored the MF format. The 
same pattern of. results was obtained when subjects lost to follow up were in- 
cluded as treatment failures in the analysis. Again, more subjects in the MF for- 
mat were abstinent than in the HF format. Differences between the MF and LF 
formats were not significant. 
Use of Nicot ine Gum 
Nicotine Polacrilex (Nicorette, Marion Merrell Dow Pharmaceuticals) was 
available as a temporary adjunct to group treatment. When used this way, most 
studies show that nicotine gum increases long-term quit rates (e.g., Hall, 
Tunstall, Rugg, Jones, & Benowitz, 1985; Hjalmarson, 1984; Killen, Fortmann, 
Newman, & Varady, 1990). Thirty-five subjects (56%) used nicotine gum. Chi- 
square analyses indicated no significant differences in gum use between the LF, 
MF, and HF treatment formats, X2(2) = .73, n.s., or between abstinent and re- 
lapsed smokers at 1-year follow-up, X2(1) = 1.01, n.s. 
Patient-Treatment Interactions 
Hierarchical logistic regression analyses (Kelsey, Thompson, & Evans, 1986) 
were used to test whether any of  the patient characteristics (pretreatment smok- 
ihg rate, nicotine dependence, motivation, self-efficacy, stress) interacted with 
treatment format to predict dichotomously scored outcomes (smoking status at 
end-of-treatment and 1-year follow-up). 
In the first regression analysis, the predictors entered were pretreatment 
smoking rate, treatment format, and the treatment format by pretreatment 
smoking rate. The interaction of Pretreatment Smoking Rate x Treatment For- 
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mat significantly predicted end-of-treatment smoking status, improvement X2(2) 
= 10.9, p < .01; goodness-of-fit ×2(72) = 75.8, p = .35. For those patients as- 
signed to the MF and HF groups, the probability of  quitting decreased as pre- 
treatment smoking rate increased. For those patients who received the LF 
format, end-of-treatment outcome was unaffected by pretreatment smoking 
rate. The interaction of  treatment format with nicotine dependence (TQ score) 
did not predict end-of-treatment cessation status. There were no significant in- 
teractions for pretreatment smoking rate or nicotine dependence when logistic 
regression models were used to predict 1-year outcomes. Psychological variables 
(motivation, self-efficacy, stress) failed to predict any of  the outcome measures in 
an interaction with treatment type. 
DISCUSSION 
The study presented here evaluated a clinic-based behavioral-pharmacological 
smoking cessation treatment delivered in three formats of  varying session fre- 
quency. Individuals receiving the LF format showed smaller smoking reductions 
and were more likely to drop out over the course of  treatment. Retention in 
treatment and end-of-treatment abstinence rates clearly favored the shorter for- 
mats. One-year abstinence rates, with and without dropouts counted as failures, 
were highest in the MF format as compared to the LF and HF formats. All other 
factors being equal, the MF format appeared to augment treatment outcome. 
A significant pat ient- treatment  interaction effect was found for pretreat- 
ment smoking rate. The low-frequency treatment session format appeared to be 
equally effective, regardless of  pretreatment smoking level. On the other hand, 
the medium- and high-frequency treatment session formats were most success- 
ful in inducing abstinence among those considered "lighter" smokers at pre- 
treatment. These results have implications for matching in clinic practice. A 
more rapid rate reduction and quitting approach may be more appropriate for 
those individuals who enter treatment smoking fewer cigarettes; conversely, a 
slower, more gradual smoking cessation format may be detrimental to their ces- 
sation efforts. Because we did not collect sufficiently detailed data on group 
process variables, it is unknown how the shorter formats, especially the MF for- 
mat, effected their influence. More frequent treatment sessions may have facili- 
tated the development of  greater group cohesiveness, friendship, and support,  
thereby explaining the greater success in initial smoking reduction and quitting 
for the MF and HF formats. 
An alternative explanation relates to readiness for behavior change. The pres- 
ent sample was comprised of  patients who scored fairly high on self-efficacy and 
perceived low stress. Moreover, the sample as a whole was highly motivated to 
quit smoking and could be conceptualized as being in what has been called the 
action stage (Prochaska, DiClemente, & Norcross, 1992). Prepared for action, 
smokers highly motivated to quit may experience a "critical period" during 
which their chances for initial cessation are optimal, possibly owing to high mo- 
tivation. For the LF format subjects, this critical period may have passed prior to 
their scheduled quit dates. 
Why so many HF format subjects initially quit only to relapse as compared to 
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subjects in the LF format (low quit and low relapse rates) and MF format (high 
quit and low relapse rates) is unknown. It is possible that some LF subjects 
dropped out of  treatment because their initial motivation waned; this suggests 
that subjects who completed treatment were more motivated to quit and sur- 
vived a lengthy 4-week weeding out process. Such individuals might be less likely 
to relapse. Likewise, the HF format's brevity may have enabled even the least 
motivated smokers to quit initially only to relapse later because of  an inadequate 
interval of  postcessation supervision. The MF format may have exerted its ef- 
fects via a combination of  the benefits of the LF and HF formats. That  is, it could 
have been sufficiently short to enable less motivated subjects to quit initially and 
sufficiently long to provide sufficient immediate postcessation support. 
Study limitations must be considered when interpreting the present findings. 
First and foremost, this study's design was not experimental and did not involve 
random assignment of  subjects to treatment formats. Consequently, statements 
concerning causality are tentative and speculative. Nevertheless, subjects did not 
self-select treatment format, no subject characteristic determined format assign- 
ment, and the groups were comparable on demographic and smoking history 
variables. Second, we utilized carbon monoxide analysis for verifying 1-year 
smoking status. Although this procedure is a methodological improvement over 
self-report only, one disadvantage is CO's relatively short half-life, approx- 
imately 4 hours, compared to other more sensitive biochemical indices of  smok- 
ing, such as cotinine assays (Benowitz, 1983). However, it is unlikely that 
nonabstinent subjects reporting at the 1-year follow-up would abstain for the 
necessary length of  time simply to lower their CO measurement. Third, the TIP 
treatment was offered in a large medical center located within a large metro- 
politan area. Subjects were either medical center employees or lived in the met- 
ropolitan area and were less inconvem,..nced by session frequency than subjects 
living in more rural areas who would have had to travel longer distances to at- 
tend treatment sessions. Consequently, the present results may not apply to such 
populations. Fourth, the sample size was limited and precluded the examination 
of  gender effects. Finally, the high attrition rate may be problematic; however, 
dropout  was a dependent  variable expected to differ based on treatment format. 
We opted for a conservative definition of  dropouts as "treatment failures"; yet 
the validity of  this assumption cannot be determined. 
At the very least, the present results highlight the importance of  comprehen- 
sive data collection, follow-up, and program evaluation in commercial smoking 
cessation programs. Although our results may not generalize to all smoking ces- 
sation programs, they appear valid in our program's setting. We have adopted 
the medium-frequency format exclusively because we get generally better results 
when using it. To the extent that the results of  smoking cessation research be- 
come incorporated into commercial programs (and program formats change as 
a result), periodic evaluation of  treatment success is important to determine 
whether new components augment, truncate, or have neutral effects on treat- 
ment success in a given setting. 
Intensive multisession group programs probably will continue to serve a mi- 
nority of  smokers. Identifying patient characteristics that are most related to 
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f a v o r a b l e  o u t c o m e ,  a n d  t hen  u s i n g  this i n f o r m a t i o n  to ass ign  p a t i e n t s  to t he  
mos t  a p p r o p r i a t e  t r e a t m e n t s ,  s h o u l d  i n c r e a s e  t he  overa l l  e f f e c t i ve ne s s  o f  s m o k -  
i ng  i n t e r v e n t i o n  p r o g r a m s .  U n t a n g l i n g  c o m p l e x  p a t i e n t - p r o g r a m  i n t e r a c t i o n s  
is a m a j o r  c h a l l e n g e  fac ing  r e s e a r c h e r s  in the  t r e a t m e n t  o f  a d d i c t i v e  behav io r s .  
T h i s  s tudy ' s  r e t r o s p e c t i v e  resu l t s  h i g h l i g h t  the  n e e d  fo r  p r o s p e c t i v e  inves t iga -  
t ions  o f  t he  e f fec t s  o f  t r e a t m e n t  cha rac te r i s t i c s .  
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